论文部分内容阅读
目的:探讨瑞舒伐他汀短期强化治疗对急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后心肌灌注、水溶性凝聚素样氧化低密度脂蛋白受体-1(sLOX-1)及炎症因子的影响。方法:抽取2019年1月至2020年1月焦作市人民医院行PCI的104例ACS患者，随机均分为研究组(瑞舒伐他汀短期强化治疗)和对照组(常规治疗)，每组52例。比较两组治疗1个月后心肌灌注情况，两组治疗前及治疗1个月后炎症因子如超敏C反应蛋白(hs-CRP)、白细胞介素-35(IL-35)、疾病相关因子如sLOX-1、内皮细胞微粒(EMPs)水平，两组主要不良心血管事件发生率及药物不良反应发生情况。结果:治疗1个月后，研究组心肌灌注Ⅲ级人数高于对照组(n P<0.05)，研究组hs-CRP、sLOX-1、EMPs水平低于治疗前及同期对照组，IL-35水平高于治疗前及同期对照组(n P0.05)。n 结论:瑞舒伐他汀短期强化治疗能够改善ACS患者PCI术后心肌灌注，降低机体炎症反应，同时不增加主要不良心血管事件及药物不良反应的发生风险，安全性较好。“,”Objective:To investigate the effects of short-term intensive treatment withrosuvastatin on myocardial perfusion, soluble lectin-like oxidized low-density lipoproteinreceptor-1 (sLOX-1) and inflammatory factors in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI).Methods:A total of 104 patients with ACS undergoing PCI in Jiaozuo People’s Hospital from January 2019 to January 2020 were selected, and randomly divided into study group (short-term intensive treatment with rosuvastatin) and control group (conventional treatment), with 52 cases in each group. The myocardial perfusion was compared between the two groups after 1 month of treatment, and the levels of inflammatory factors such as high-sensitivity C-reactive protein (hs-CRP), interleukin-35 (IL-35) anddisease-related factors such as sLOX-1, endothelial microparticles (EMPs) were compared between the two groups before treatment and after 1 month of treatment. The occurrence of major adverse cardiovascular events and adverse drug reactions were compared between the two groups.Results:After 1 month of treatment, the number of patients with myocardial perfusion grade III in study group was significantly higher than that in control group (n P<0.05), the levels of hs CRP, sLOX-1 and EMPs in the study group were lower than those in the control group before treatment and at the same period, and the levels of IL-35 were higher than those in the control group before treatment and at the same period (n P0.05).n Conclusions:Short-term intensive treatment with rosuvastatin can improve myocardial perfusion and reduce the body’s inflammatory response of patients with ACS after PCI, and it will not increase the risks of major adverse cardiovascular events and adverse drug reactions, with good safety.